Reagan-Udall Foundation for the FDA

Join us August 5, in collaboration with the U.S. Food and Drug Administration, for Drug Repurposing: Considerations for Selection Criteria and Prioritization, a hybrid public meeting to discuss opportunities to expand treatment options for patients by identifying new uses for approved drugs.

During the meeting, the public is invited to provide brief comments addressing key repurposing questions. The deadline to request to present public comment is Tuesday, July 21.

Learn more and register: https://reaganudall.org/news-and-events/events/drug-repurposing-unmet-medical-needs

The Reagan-Udall Foundation for the FDA is closed today in recognition of the holiday weekend. Happy !

How can we accelerate drug development and safely reduce our reliance on animal testing?

Our new report, “Advancing Drug Development by Reducing Reliance on Animal Testing,” summarizes a recent public meeting where the U.S. Food and Drug Administration, patient advocates, regulated industry, and researchers explored strategies to do so.

Read the full report: https://reaganudall.org/publications/advancing-drug-development-reducing-reliance-animal-testing

Materials are now available from our public meeting, Affecting the Aging Trajectory: Regulatory Constructs for Gerotherapeutic Drug, Biologic & Device Development.

This May 27 public meeting explored regulatory considerations for interventions that may improve health throughout the lifespan, including intrinsic capacity, function-centered endpoints, and the potential for an “Adult Health Curve.”

View the recordings, slides, speaker bios, and transcripts here:
https://www.reaganudall.org/news-and-events/events/affecting-aging-trajectory-regulatory-constructs-gerotherapeutic-drug